| DC46604 |
CMD178
|
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling. CMD178 also is an inhibitor of STAT5 and inhibit Treg cell development. |
| DC10139 |
Stat5 Inhibitor(STAT5-IN-1)
|
Stat5 Inhibitor is a cell permeable nonpetidic nicotinoyl hydrazone which suppresses Stat5 via binding to the SH2 domain. |
| DC10105 |
SH5-07
|
SH5-07 is a hydroxamic acid based Stat3 inhibitor with an IC50 of 3.9±0.6 μM in in vitro assay. |
| DC7983 |
SH-4-54
|
SH-4-54 is a potent STAT inhibitor with KD of 300 nM and 464 nM for STAT3 and STAT5, respectively. |
| DC9691 |
Piperlongumine
|
Piperlongumine induces cell death and increases the level of reactive oxygen species (ROS) in cancer cells with both wild-type and normal p53. |
| DC8474 |
Napabucasin (BBI608)
|
Napabucasin (BBI608) is an orally-administered small molecule which can block cancer stem cell (CSC) self-renewal and induces cell death in CSCs as well as non-stem cancer cells. |
| DC10555 |
inS3-54A18
|
inS3-54A18 is a potent STAT3 inhibitor, with anti-cancer properties. |
| DC7751 |
FLLL32
|
FLLL32, a novel curcumin analogue, is a potent STAT3 inhibitor. |
| DC10864 |
C188-9
|
C188-9 is a potent inhibitor of STAT3 that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors. |
| DC8040 |
STAT3 Inhibitor XVIII, BP-1-102
|
BP-1-102 is a potent, orally bioavailable and selective STAT3 inhibitor. |
